Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.815
EU - Europa 2.899
AS - Asia 1.952
SA - Sud America 83
AF - Africa 14
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.771
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.670
SG - Singapore 958
RU - Federazione Russa 671
HK - Hong Kong 621
IE - Irlanda 560
SE - Svezia 516
IT - Italia 441
DE - Germania 397
CN - Cina 266
CA - Canada 136
BR - Brasile 71
GB - Regno Unito 69
AT - Austria 63
UA - Ucraina 48
VN - Vietnam 42
ID - Indonesia 34
FR - Francia 30
NL - Olanda 23
FI - Finlandia 21
RO - Romania 16
DK - Danimarca 12
CH - Svizzera 8
IN - India 7
MX - Messico 6
AU - Australia 5
MU - Mauritius 5
GR - Grecia 4
IL - Israele 4
JP - Giappone 4
PL - Polonia 4
IR - Iran 3
AR - Argentina 2
BD - Bangladesh 2
CL - Cile 2
CZ - Repubblica Ceca 2
ES - Italia 2
KZ - Kazakistan 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CO - Colombia 1
CR - Costa Rica 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GN - Guinea 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NO - Norvegia 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 11.771
Salva come PNG Salva come JPEG
Città #
Ann Arbor 980
Fairfield 840
Singapore 659
Hong Kong 616
Dublin 558
Woodbridge 412
Ashburn 406
Wilmington 369
Chandler 368
Houston 348
Princeton 308
Frankfurt am Main 291
Cambridge 281
New York 272
Seattle 260
Santa Clara 184
Altamura 140
Lawrence 140
Jacksonville 138
Beijing 112
Ottawa 80
Milan 79
San Diego 79
Moscow 53
Andover 46
Toronto 46
Nuremberg 40
Council Bluffs 36
Vienna 36
Falls Church 31
Jakarta 28
Shanghai 27
Redmond 24
Chicago 23
Dearborn 22
Dong Ket 20
Nanjing 20
London 19
Norwalk 17
Helsinki 14
Florence 12
Buffalo 11
Los Angeles 11
Chengdu 10
Rome 10
Wuhan 10
Boardman 9
Fara Gera d'Adda 9
Guangzhou 9
Phoenix 9
Fuzhou 8
Paris 7
Reggio Calabria 7
Shenyang 7
Hefei 6
Kilburn 6
Lachine 6
San Mateo 6
Bonndorf 5
Hounslow 5
Jinan 5
Newark 5
Shenzhen 5
Boulder 4
Bucharest 4
Casoria 4
Catania 4
Cologne 4
Fort Lauderdale 4
Hangzhou 4
Laurel 4
New Bedfont 4
Padova 4
São Paulo 4
Aiud 3
Bergamo 3
Brasília 3
Chennevières-sur-Marne 3
Dallas 3
Groningen 3
Hebei 3
Huizen 3
Islington 3
Leawood 3
Modena 3
Nanchang 3
New Delhi 3
Oradea 3
Pavia 3
Pisa 3
Pully 3
Taizhou 3
Tel Aviv 3
Trumbull 3
Udine 3
Almaty 2
Amsterdam 2
Arnsberg 2
Baotou 2
Bologna 2
Totale 8.717
Salva come PNG Salva come JPEG
Nome #
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 212
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 206
Treatment of venous thromboembolism with tinzaparin in oncological patients 201
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 197
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 177
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 151
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 144
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 143
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 141
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 138
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 128
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 127
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 125
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 120
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 120
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 119
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 117
Laboratory haemostasis monitoring in COVID-19 114
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 112
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 103
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 102
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 102
DOACs and “newer” hemophilia therapies in COVID-19: Reply 102
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 102
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 101
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 101
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 100
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 100
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 100
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 99
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 98
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 97
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 97
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 97
Hemostatic biomarkers in occult cancer and cancer risk prediction 96
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 94
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 94
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 94
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 93
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 93
Molecular basis for the relationship between thrombosis and cancer 92
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 90
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 89
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 89
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 89
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 88
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 88
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 88
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 88
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 88
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 87
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 87
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 86
Procoagulant mechanisms in tumour cells 85
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 85
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 85
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 83
The mechanisms of cancer-associated thrombosis 82
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 82
Clozapine-induced anemia: A case-report 82
Cancer and venous thromboembolism 81
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 81
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 80
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia 80
The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence - 15 Years and Counting 79
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 79
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 78
External validation of the DASH prediction rule: a retrospective cohort study 78
Risk of Venous Thromboembolism in Surgical Elderly Patients. 77
Venous thromboembolism in the hematologic malignancies 77
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016 76
Thrombosis in myeloproliferative neoplasms 75
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 75
Pharmacological inhibition of thromboxane-synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. 75
Acute Promyelocytic Leukemia Coagulopathy. 75
The Italian START-Register on anticoagulation with focus on atrial fibrillation 75
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 75
Tromboxane synthetase inhibition results in increased platelet sensivity to prostacyclin. Thrombosis and Haemostasis 74
Type and dose of heparin in Covid-19: Reply 74
Thrombin generation predicts early recurrence in breast cancer patients 74
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 73
Microparticles in tumor progression 73
Soluble stroma-related biomarkers of pancreatic cancer 73
Several murine metastatizing tumors possess a cysteine proteinase with cancer procoagulant characteristics 73
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 72
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 71
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 71
International Forum on GMP-grade human platelet lysate for cell propagation 70
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 70
Hemostatic biomarkers in cancer progression 69
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia 68
Treatment of thromboembolism in cancer patients 68
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 68
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 68
Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells 67
V. Plasmaferesi terapeutica 67
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 66
Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer 65
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 65
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review 65
Totale 9.510
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.160
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.160
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020423 0 0 0 0 0 0 0 0 0 155 179 89
2020/20212.650 269 278 354 163 137 214 287 296 173 162 187 130
2021/20221.551 160 169 178 92 61 74 93 102 68 97 110 347
2022/20232.055 369 575 190 140 96 407 7 91 97 17 41 25
2023/20241.482 27 52 20 18 227 407 262 46 245 20 5 153
2024/20252.877 306 732 200 167 356 74 291 96 417 238 0 0
Totale 12.450